

**MULTIPLE ACTING ANTI-ANGIOGENIC AND CYTOTOXIC  
COMPOUNDS AND METHODS FOR USING THE SAME**  
**GOVERNMENT CONTRACT**

This work was supported in part by the National Institutes of Health,  
5 U.S. Department of Health and Human Services under Contract Nos. R01 AI44661-  
03 and R01 CA89300-01. The Government may have certain rights in this invention.

**FIELD OF THE INVENTION**

This invention relates to pyrimidine compounds and pharmaceutically  
acceptable salts, solvates and prodrugs thereof. The present compounds have been  
10 found useful as antitumor and antiangiogenic agents. Methods using these  
compounds are also provided.

**BACKGROUND OF THE INVENTION**

Angiogenesis, the formation of new blood vessels, occurs during  
development and in normal adults during wound healing, pregnancy, and corpus  
15 luteum formation. Although angiogenesis is limited in normal adults, it is induced in  
many disease states including cancer, diabetic retinopathy, rheumatoid arthritis,  
psoriasis, atherosclerosis, and restenosis (reviewed in Folkman, 1995).

Tumors require angiogenesis to grow beyond 1-2 mm<sup>3</sup>. (Folkman,  
1990). The increased blood flow to the tumor allows for continued growth as well as  
20 metastasis because successful metastasis requires the presence of blood vessels to  
allow for the tumor cells to enter the circulation. The close interplay between  
angiogenesis and metastasis contributes to the poor prognosis seen in patients with  
highly angiogenic tumors. Cherrington *et al.*, 2000.

Some of the most well characterized regulators of angiogenesis are  
25 growth factors and receptor tyrosine kinases (RTKs) involved in the migration and  
proliferation of endothelial cells. Of primary interest for angiogenesis are Flt-1 and  
Flk-1/KDR, the receptors for vascular endothelial growth factor (VEGF), as well as  
Tie 1 and Tie 2/Tek, the receptors for angiopoietins. These four receptors are  
expressed primarily on endothelial cells and play a direct role in angiogenesis.  
30 Additional RTKs with broader expression patterns implicated in angiogenesis are  
platelet-derived growth factor receptors (PDGFRs); fibroblast growth factor receptors  
(FGFRs); the hepatocyte growth factor/scatter factor (HGF/SF) receptor, Met; and

epidermal growth factor receptors (EGFRs), although it is thought that the EGFR is likely to act predominantly in directly driving the growth of tumor cells rather than through angiogenesis. Cherington *et al.*, 2000.

VEGF is a dimeric protein also known as vascular permeability factor  
5 because it acts on endothelial cells to regulate permeability of those cells as well as their proliferation. These two activities are mediated through its tyrosine kinase receptors, VEGFR1/Flt-1 and VEGFR2/Flk-1/KDR (KDR is the human homologue of Flk-1). VEGF and its receptors are expressed in angiogenic tissues during development, wound healing and other situations when angiogenesis occurs. The role  
10 of VEGF in tumor angiogenesis has also been clearly demonstrated using tumor models in rodents (reviewed in Hanahan, 1997; Shawver *et al.*, 1997); there is an extensive literature exists linking VEGF with human cancers such as pulmonary adenocarcinoma (Takanami *et al.*, 1997) and non-small cell carcinoma (NSCLC) (Fontanini *et al.*, 1999; Takahama *et al.*, 1998; Ohta *et al.*, 1996). Survival of patients  
15 with VEGF-positive tumors was significantly less than patients with VEGF-negative tumors. For example, in one study of non-small cell carcinoma (NSCLC), patients with low VEGF levels had a median survival time of 151 months, whereas those with high VEGF expression had a mean survival time of only 8 months. Ohta *et al.*, 1996.

VEGF and its receptors, in particular, serve as excellent targets for  
20 anti-angiogenesis therapy because KDR is an endothelial cell-specific VEGF receptor expressed primarily during the angiogenic process. The VEGF signaling cascade has been validated as a target for therapeutic intervention by several methods. See, e.g., Saleh *et al.*, 1996, Claffey *et al.*, 1996, Kim *et al.*, 1993 and Asano *et al.*, 1995.

Epidermal growth factor (EGF) is one of several naturally occurring  
25 proteins that promotes normal cell proliferation in a tightly regulated manner by binding to its receptor, EGFR, and sending growth signals via the receptor tyrosine kinase enzyme activity to the nucleus of the cell and thus controlling growth. In many human cancers, EGFR is either overexpressed or mutated, leading to aberrant signaling and the development of a tumor; thus inhibition of EGF receptor kinase is  
30 also a target in anti-tumor therapy.

Many pyrimidine systems have been studied for their ability to inhibit growth of tumors, through inhibition of angiogenesis and/or inhibition of cell growth,

by targeting receptor tyrosine kinases. See, for example, Sun, Li and McMahon, G. "Inhibition of tumor angiogenesis by Synthetic Receptor Tyrosine Kinase Inhibitors". *Drug Discov Today* 2000, 5 (8): 344-353, and Traxler, P. and Furet, P., "Strategies toward the Design of Novel and Selective Protein Tyrosine Kinase Inhibitors" *Pharmacol. Ther.* 1999 82 (2-3): 195-206, which disclose synthetic pyrimidine compounds which have been shown to be effective TK inhibitors.

Pyrimidine systems have also been shown to inhibit dihydrofolate reductase (DHFR) enzyme activity. Because DHFR reduces dihydrofolate to tetrahydrofolate, inhibition of DHFR deprives the cell of tetrahydrofolate, without which the cell cannot produce 5,10-methylene-tetrahydrofolate, essential for cell growth. The inhibition of DHFR results in the inhibition of DNA synthesis and leads to cell death.


Additionally, some pyrimidine derivatives are known to function as thymidylate synthase (TS) inhibitors. TS, along with DHFR, forms part of the system responsible for the synthesis of deoxythymidylate (dTMP) from deoxyuridylate (dUMP). TS catalyzes the sole de novo synthesis of dTMP from dUMP. Inhibition of TS, therefore, deprives the cell of thymidine, which is an essential constituent of DNA.

In general, it is highly desirable to develop new antiangiogenic compounds which inhibit formation of new blood vessels and development of a new blood supply, as these can selectively target various tumor types and prevent growth of circulation in the tumor and inhibit metastasis. Because angiogenesis is limited in healthy adults, compounds which inhibit angiogenesis can selectively target tumors as compared with other compounds and anti-cancer agents using other modes of action, which often indiscriminately act on tumor and healthy cells alike. There is a need for compounds which provide the desired enzyme inhibition with a high degree of selectivity and low toxicity.

#### SUMMARY OF THE INVENTION

The present invention provides pyrimidine compounds, and pharmaceutically acceptable salts, solvates and prodrugs thereof, having the formula (1):

Q'  
Cont



where X, X<sub>1</sub>, X<sub>2</sub>, X<sub>3</sub> and X<sub>4</sub> are from one to about three atoms, are the same or different and are independently selected from the group consisting of hydrogen, an alkyl group, a alkenyl group, an heteroalkyl group and an heteroalkenyl group,

and any carbons or nitrogens of said alkyl group, alkenyl group, heteroalkyl group or heteroalkenyl group can optionally be substituted with a straight, branched or cyclic lower alkyl group of from 1 to about 6 carbons;

Z is selected from the group consisting of C, CH, CH<sub>2</sub>, N, NH, S, O, CH=CH, CH=N and N=CH;

L is selected from the group consisting of C, CH, CH<sub>2</sub>, N, NH, S, O, CH=CH, CH=N and N=CH, but when Z is C, CH, CH=CH or CH<sub>2</sub> then L is N, NH, S or O;

M is selected from the group consisting of carbon and CH;

the chemical bond between L and M is selected from the group consisting of a single bond and a double bond, and M is carbon when the bond is a double bond, and M is CH when the bond is a single bond;

the chemical bond between M and Z is selected from the group consisting of a single bond and a double bond, and M is carbon when the bond is a double bond, and M is CH when the bond is a single bond;

but when the bond between L and M is a double bond the bond between M and Z is a single bond;

at least one of R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub>, or R<sub>5</sub> is present;

Q'  
cond

R<sub>1</sub>, R<sub>4</sub> and R<sub>5</sub> are the same or different and are selected from group consisting of hydrogen, a cyclic aliphatic group, a cyclic heteroaliphatic group, an aryl group, a heteroaryl group, an alkylaryl group, a alkylheteroaryl group, a substituted aryl group, a substituted heteroaryl group, a substituted alkylaryl group and a substituted alkylheteroaryl group;

R<sub>2</sub> and R<sub>4</sub> are optional, are the same or different and are selected from group consisting of hydrogen, a cyclic aliphatic group, a cyclic heteroaliphatic group, a cyclic aromatic group, a heterocyclic aromatic group, an aryl group, a heteroaryl group, an alkylaryl group, a alkylheteroaryl group, a substituted aryl group, a substituted heteroaryl group, a substituted alkylaryl group, a substituted alkylheteroaryl group, and *p*-aroyl-glutamate;

and each substituent of any substituted group is the same or different and is selected from the group consisting of a straight, branched or cyclic lower alkyl, alkenyl or alkynyl group of from one to about 6 carbons, an alkoxy group, an alkoxyaryloxy group, and a halogen.

In one aspect of the present invention, these pyrimidine compounds can function as receptor tyrosine kinase inhibitors, and prevent the development of new blood vessels in tumors. Specifically, these compounds have been found to inhibit several receptor tyrosine kinases, including vascular endothelial growth factor (VEGF), epidermal growth factor (EGF) and platelet derived growth factor (PDGF) receptor tyrosine kinases. Thus, the compounds of the present invention are dual acting in that they can inhibit angiogenesis by inhibiting tyrosine kinases directly involved in angiogenesis, (such as by inhibiting the VEGF receptor tyrosine kinase), and inhibit receptor tyrosine kinases involved in cell growth, for example, by competitively binding to TK receptors such as the EGF receptor tyrosine kinase. These compounds have an antiangiogenic and an antitumor effect.

In an additional aspect of the present invention, certain of these pyrimidine compounds function as triple or quadruple acting agents. That is, they inhibit receptor tyrosine kinases, and they also inhibit DHFR and/or thymidylate synthase, thus further providing additional inhibition of tumor growth. Both the dual, triple and quadruple acting compounds are unique in their ability to provide multiple mechanisms of action in structurally distinct compounds. None of the existing

compounds known to inhibit receptor tyrosine kinases are known to additionally inhibit DHFR and/or TS, nor do any have the distinct chemical structures described and claimed herein. It is thought that the compounds having less bulky substituents at the 4-position on the pyrimidine ring are able to provide the multiple mechanisms of action, although the inventor does not wish to be bound by this.

Methods for using these compounds in the treatment of various illnesses are also within the scope of the invention; for example, these compounds are useful for therapeutic and/or prophylactic purposes as antitumor or anti-angiogenic agents or to otherwise destroy or minimize growth or proliferation of cancerous cells in cancer patients or in the treatment of other illnesses.

It is an object of the present invention, therefore, to provide pyrimidine derivative compounds, and pharmaceutically acceptable salts and prodrugs thereof, having antitumor and/or anti-angiogenic activity.

It is an additional object of the present invention to provide pyrimidine compounds, and pharmaceutically acceptable salts and prodrugs thereof, for substantially inhibiting receptor tyrosine kinase(s) activity.

It is a further object of this invention to provide pyrimidine compounds, and pharmaceutically acceptable salts and prodrugs thereof, for substantially inhibiting receptor tyrosine kinases and/or dihydrofolate reductase and/or thymidylate synthase enzymes.

It is an additional object of this invention to provide a method of the present pyrimidine compounds and their derivatives to treat various illnesses such as cancer.

These and other aspects of the invention will be more fully understood from the following detailed description of the invention, the drawings and the claims appended hereto.

#### BRIEF DESCRIPTION OF THE DRAWINGS

The invention is further illustrated by the following non-limited figures in which:

Figure 1 shows the results of the CAM assay procedure.


Figure 2 shows a schematic diagram of methods of preparing the 2-amino 6-substitute pyrrolo [2,3-*d*] pyrimidines of the present invention.

Figure 3 shows a schematic diagram of the methods of preparing 2,4-diamino 5-substituted furo [2,3-*d*] pyrimidines.

Figures 4a and 4b show results of the phospho-EGFR and phospho-Flk1 assay for the triple acting compounds.

#### DETAILED DESCRIPTION OF THE INVENTION

The present invention is directed to compounds, and pharmaceutically acceptable salts, solvates, and prodrugs thereof, having formula (1):



where X, X<sub>1</sub>, X<sub>2</sub>, X<sub>3</sub> and X<sub>4</sub> are from one to about three atoms, are the same or different and are independently selected from the group consisting of hydrogen, an alkyl group, an alkenyl group, a heteroalkyl group and a heteroalkenyl group,

and any carbons or nitrogens of said alkyl group, alkenyl group, heteroalkyl group or heteroalkenyl group can optionally be substituted with a straight, branched or cyclic lower alkyl group of from 1 to about 6 carbons;

Z is selected from the group consisting of C, CH, CH<sub>2</sub>, N, NH, S, O, CH=CH, CH=N and N=CH;

L is selected from the group consisting of C, CH, CH<sub>2</sub>, N, NH, S, O, CH=CH, CH=N and N=CH, but when Z is C, CH, CH=CH or CH<sub>2</sub> then L is N, NH, S or O;

M is selected from the group consisting of carbon and CH;

A<sup>2</sup>  
cont

the chemical bond between L and M is selected from the group consisting of a single bond and a double bond, and M is carbon when the bond is a double bond, and M is CH when the bond is a single bond;

the chemical bond between M and Z is selected from the group consisting of a single bond and a double bond, and M is carbon when the bond is a double bond, and M is CH when the bond is a single bond;

but when the bond between L and M is a double bond the bond between M and Z is a single bond;

at least one of R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub>, or R<sub>5</sub> is present;

R<sub>1</sub>, R<sub>4</sub> and R<sub>5</sub> are the same or different and are selected from group consisting of hydrogen, a cyclic aliphatic group, a cyclic heteroaliphatic group, an aryl group, a heteroaryl group, an alkylaryl group, a alkylheteroaryl group, a substituted aryl group, a substituted heteroaryl group, a substituted alkylaryl group and a substituted alkylheteroaryl group;

R<sub>2</sub> and R<sub>3</sub> are the same or different and are selected from group consisting of hydrogen, a cyclic aliphatic group, a cyclic heteroaliphatic group, an aryl group, a heteroaryl group, an alkylaryl group, a alkylheteroaryl group, a substituted aryl group, a substituted heteroaryl group, a substituted alkylaryl group, a substituted alkylheteroaryl group, and *p*-aroyle-glutamate;

and each substituent of any substituted group is the same or different and is selected from the group consisting of a straight, branched or cyclic lower alkyl, alkenyl or alkynyl group of from one to about 6 carbons, an alkoxy group, an alkoxyaryloxy group, and a halogen.

As used herein, the term "lower alkyl" group refers to those lower alkyl groups having one to about six carbon atoms, such as for example methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclohexyl, cyclopropylmethyl or cyclobutylmethyl groups. Alkyl groups sharing one to about six carbon atoms are preferred. These lower alkyl groups are straight chain, branched chain or cyclic (alicyclic hydrocarbon) arrangements. The carbon atoms of these straight chain, branched chain or cyclic arranged alkyl groups may have one or more substituents for the hydrogens attached to the carbon atoms.



As used herein, the terms "heteroalkyl" and "heteroalkenyl" will be used to refer to alkyl or alkene chains from one to about 3 atoms where one or more of the carbons has been replaced with nitrogen, oxygen or sulfur. Thus "heteroalkyl" and "heteroalkenyl" groups will include, for example, C-C-N, C-S, S-C, C-O, C-C-O, O-C, N-C-C, N-C=C and other various combinations, as will be apparent to one skilled in the art. The above list is not meant to be exhaustive, and many combinations are contemplated as within the scope of the present invention.

"Aryl" groups, as used herein, will refer to compounds whose molecules have an aromatic ring structure, such as the six-carbon ring of benzene, or multiple rings which are either fused or unfused, such as condensed six-carbon rings of other aromatic derivatives. The term "aryl" is also defined to include diaryl, triaryl and polyaryl groups, which would have two, three or more rings, respectively. Thus, suitable aryl groups would include, for example, phenyl, biphenyl, naphthyl, phenanthrene, anthracene groups and aryl oxyaryl groups. This list is not meant to be exhaustive, and any aryl group, as these terms are defined above and commonly understood in the art, are within the scope of the present invention.

The term "heteroaryl", as used herein, will be used to refer to aromatic ring structures having at least one atom in the ring which is not carbon, such as oxygen, nitrogen or sulfur. "Heteroaryls" as used herein also refers to aromatic ring structures that are part of larger ring structures, such as two or three member ring systems, which may be fused or unfused, in which one of the rings is as described above. Thus, "heteroaryl" can refer to ring systems in which one or more rings contain a heteroatom and one or more rings do not. It will be understood that this list is not meant to be exhaustive, and that any heteroaryl group, as these terms are defined above and commonly understood in the art, are within the scope of the present invention. Examples include but are not limited to pyrroles, thiophenes, furans, imidazoles, and the like, as well as fused ring structures having rings of different sizes, such as benzofurans, indoles, purines, and the like.

Also included within the scope of the present invention are cyclic aliphatic (or "alicyclic") groups, as that term is understood in the art, and heterocyclic groups. As used herein, the term "heterocyclic group" will refer to non-aromatic

a3  
cont

cyclic substituents in which one or more members of the ring is not carbon, for example oxygen, sulfur or nitrogen.

The terms "alkylaryl" (or "alkaryl") or "alkylheteroaryl" as used herein will refer to groups having an alkyl moiety attached to an aryl or heteroaryl ring. The  
5 alkyl moiety is preferably a straight, branched or cyclic alkyl group having one to about six carbon atoms. This alkyl moiety may also contain oxygen, nitrogen or sulfur atoms, and can therefore be an alkoxy group. The aryl or heteroaryl moiety of the alkylaryl group is a substituted or unsubstituted aryl or heteroaryl group, as these terms are described above. As used herein, the terms "alkylaryl" or "alkylheteroaryl"  
10 will also be used to refer to arylalkyl groups or heteroarylalkyl groups, as those terms are understood in the art, and will denote attachment of such a substituent at either the alkyl or the aryl portion of the group. Thus, for example, a benzyl group would be embraced by the term "alkylaryl".

Any of the cyclic substituents described above, such as the aryl,  
15 heteroaryl, alkylaryl, alkylheteroaryl, alicyclic, or heterocyclic groups are optionally substituted with one or more substituents as listed above. In the case of more than one substituent, the substituents are independently selected. "Alkoxy groups" and "alkyl groups" include straight or branched chains having up to about six members. "Halogen" refers to chlorine, bromine, iodine and fluorine. "Aryl and heteroaryl  
20 groups" are as described above. When a carboxylic acid is a substituent, it will be appreciated that the moiety represents an acid such as benzoic acid. "Acyl" refers to an organic acid group in which the OH is replaced by some other substituent, and is generally designated as RCO- where R is a C<sub>1-6</sub> alkyl, C<sub>2-6</sub> alkenyl, or C<sub>2-6</sub> alkynyl straight or branched chain group.


As used herein, the terms "aroyle" or "heteroaroyle", such as when used within the term *p*-aroyle-L-glutamate, refers to benzoyl, naphthoyl, thiophenoyl, furophenoyl, pyrroyle, and any other "aroyle" or "heteroaroyle" as these terms would be understood by one skilled in the art. "Aroyle" and "heteroaroyle" are generally defined in the art as an aromatic or heteroaromatic compound having a carbonyl moiety.  
30 "Glutamate" will be understood as representing both the ester form (glutamate) and the acid form (glutamic acid).

It will be appreciated by those skilled in the art that a general formula depicting compounds having side chains with adjacent carbons having a double bond will result in both *cis* and *trans* isomers as possible structures. Both the *cis* and *trans* isomers, and mixtures thereof, of any such compound within the broad general formula described in formulas (1), (2) and (3) are contemplated as being within the present invention.

Compounds of the above general formula (1) have been found to inhibit many receptor tyrosine kinases such as VEGF, EGF and other receptor tyrosine kinases and are thus dual-acting compounds; that is, they exert an anti-cancer effect by inhibiting both angiogenesis and cell growth and proliferation.

In an additional aspect of the present invention, certain compounds of the above general formula have been found to exert an additional anti-cancer effect by inhibiting dihydrofolate reductase and/or thymidylate synthase, in addition to their inhibition of receptor tyrosine kinases. These compounds are thus triple - or quadruple-acting anti-cancer agents in that they provide anti-tumor activity in multiple, distinct ways. As described above, it is thought that compounds of the above general formula (1) having less bulky substituents in the 4-position on the pyrimidine ring are able to function as receptor tyrosine kinase, DHFR and/or TS inhibitors, although the inventor does not wish to be bound by this.

In preferred embodiments, compounds of the present invention will have the general formula (2):



A4  
cont


5  
10  
15  
20  
25

where  $X_1$  is  $\text{CH}=\overset{\text{R}_6}{\text{C}}$ , and  $\text{R}_6$  is selected from the group consisting of hydrogen and a straight, branched or cyclic lower alkyl group of from 1 to about 6 carbons;

$\text{R}_2$  is selected from group consisting of hydrogen, a cyclic aliphatic group, a cyclic heteroaliphatic group, an aryl group, a heteroaryl group, an alkylaryl group, a alkylheteroaryl group, a substituted aryl group, a substituted heteroaryl group, a substituted alkylaryl group, a substituted alkylheteroaryl group, and *p*-aroyle-glutamate;

and each substituent of any substituted group is the same or different and is selected from the group consisting of a straight, branched or cyclic lower alkyl, alkenyl or alkynyl group of from one to about 6 carbons, an alkoxy group, an alkoxyaryloxy group, and a halogen.

In additional preferred embodiments, compounds of the present invention will be represented as having the general formula (3):



where  $X$  and  $X_2$  are from one to about three atoms, are the same or different and are independently selected from the group consisting of hydrogen, an alkyl group, a alkenyl group, a heteroalkyl group and a heteroalkenyl group,

and any carbons or nitrogens of said alkyl group, alkenyl group, heteroalkyl group or heteroalkenyl group can optionally be substituted with a straight, branched or cyclic lower alkyl group of from 1 to about 6 carbons;

at least one of  $\text{R}_1$  or  $\text{R}_3$  are present;

a4  
cont

5 R<sub>1</sub> is selected from group consisting of hydrogen, a cyclic aliphatic group, a cyclic heteroaliphatic group, a cyclic aromatic group, a heterocyclic aromatic group, an aryl group, a heteroaryl group, an alkylaryl group, a alkylheteroaryl group, a substituted aryl group, a substituted heteroaryl group, a substituted alkylaryl group and a substituted alkylheteroaryl group;

10 R<sub>3</sub> is selected from group consisting of hydrogen, a cyclic aliphatic group, a cyclic heteroaliphatic group, an aryl group, a heteroaryl group, an alkylaryl group, a alkylheteroaryl group, a substituted aryl group, a substituted heteroaryl group, a substituted alkylaryl group, a substituted alkylheteroaryl group, and *p*-aroyl-glutamate;

and each substituent of any substituted group is the same or different and is selected from the group consisting of a straight, branched or cyclic lower alkyl, alkenyl or alkynyl group of from one to about 6 carbons, an alkoxy group, an alkoxyaryloxy group, and a halogen.

15 As used herein, the term "pharmaceutically acceptable salts and solvates" include salts or solvates of the present pyrimidine compounds suitable for use in pharmaceutical applications. One skilled in the art would easily be able to determine whether a salt or solvate form of any given compound is suitable for use as a pharmaceutical. Examples of pharmaceutically acceptable salts include but are not  
20 limited to, acetate, formate, glucuronate, ethantate, and sulfonate. Other examples include alkaline metal, alkaline earth metal, other non-toxic metals, ammonium and substituted ammonium salts such as the sodium, potassium, lithium, calcium, magnesium, aluminum, zinc, ammonium, trimethyl ammonium, triethyl ammonium, tetrabutyl ammonium, pyridinium and substituted pyridinium salts. "Pharmaceutically  
25 acceptable prodrugs" similarly refers to any prodrug formulations of the present compounds. A prodrug will be understood by those skilled in the art as a chemical compound that is converted into an active curative agent by processes within the body. Other formulations comprising the pyrimidine compounds described herein are also within the scope of the present invention. Salts, solvates and prodrugs of the  
30 compounds of Formula 1, 2 or 3 can be made by standard methods well known to those skilled in the art.

The present invention further relates to methods of using the above-described compounds, and pharmaceutically acceptable salts and prodrugs thereof, to treat a patient with an illness. "Treating" and "treatment" are used generically throughout to refer to both therapeutic and prophylactic treating/treatment that is  
5 effected by inhibition of receptor tyrosine kinases (referred to generally as "receptor tyrosine kinase"), and of DHFR and/or thymidylate synthase. As used herein, the term "illness" refers to various types of cancer including, but not limited to, leukemia, lung cancer, colon cancer, CNS cancer, melanoma, ovarian cancer, renal cancer, prostate cancer, breast cancer, and various other illnesses such as diabetic retinopathy,  
10 rheumatoid arthritis, psoriasis, atherosclerosis, and restenosis.

A method of treating a patient for an illness according to the present invention comprises administering an effective amount of one or more compounds of Formula 1, 2 or 3 to a patient.

As used herein, the term "patient" means adult members of the animal  
15 kingdom, including, but not limited to, human beings.

As used herein, the term "effective amount" refers to that amount of any of the present compounds required to bring about a desired effect in a patient. The desired effect will vary depending on the illness being treated. For example, the desired effect may be reducing tumor size, destroying cancerous cells, preventing  
20 metastasis or reducing symptoms associated with the various other diseases listed above and contemplated as being within the treatment methods of the present invention. On its most basic level, an effective amount is that amount needed to inhibit the receptor tyrosine kinase(s) generally and/or DHFR and/or thymidylate synthase. Any amount of inhibition will yield a benefit to a patient and is therefore  
25 within the scope of the invention.

It will be appreciated that the effective amount will vary from patient to patient depending on such factors as the illness being treated, the severity of the illness, the size of the patient being treated, the patient's ability to mount an immune response, and the like. The determination of an effective amount for a given patient is  
30 within the skill of one practicing in the art. Typically an effective amount will be determined by evaluating potency in standard *ex vivo* cellular systems, followed by preclinical and clinical *in vivo* assessment.

Administration can be by any means known in the art, such as parenterally, orally or topically. The pyrimidine compound can be contained within a suitable pharmaceutical carrier for administration according to the present methods. "Suitable pharmaceutical carrier" refers to any pharmaceutical carrier known in the art that will solubilize the present compounds and will not give rise to compatibility problems and includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like. The use of such media and agents for pharmaceutical use is well known in the art. Use of any of these media or agents is contemplated by the present invention, absent compatibility problems with the chimeric proteins. Preferred carriers include physiologic saline and 5% dextrose.

It is especially advantageous to formulate parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the patients being treated, each unit containing a predetermined quantity or effective amount of pyrimidine compound to produce the desired effect in association with the pharmaceutical carrier. The specification for the dosage unit forms of the invention are dictated by and directly dependent on the particular compound and the particular effect to be achieved.

#### EXAMPLES

The following examples are intended to illustrate the invention, and should not be construed as limiting the invention in any way. Standard test procedures familiar to those skilled in the art were used in the examples, such as those procedures described by Gangjee, A., et al., in "Effect of bridge region variation on antifolate and antitumor activity of classical 5-substituted 2,4-diamino furo [2,3-*d*]pyrimidines", *J. Med. Chem.*, Vol. 38, pp. 3798-3805 (1995); and "Novel 2,4-diamino-5-substituted-pyrrolo[2,3-*d*]pyrimidines As Classical and Non-Classical Antifolate Inhibitors of Dihydrofolate Reductases", *J. Med. Chem.*, Vol. 38, pp. 2158-2165 (Jun. 6, 1995) and references disclosed therein, as well as *Angiogenesis Protocols*, J. Clifford Murray ed., Humana Press, 2001 .

### Example 1

#### *CAM assay procedure*

Human VEGF-165 and BFGF (200 ng each) were added to saturation to a microbial testing disk and placed onto the chorioallantoic membrane (CAM) of 10-day old chicken embryos. Eight hours after the growth factor treatment, unknown compounds (100µg) were added to the same microbial testing disk. Growth factors and embryos were allowed to incubate an additional 40 hours. CAMS were removed, paraformaldehyde (4% in PBS) fixed, placed onto Petri dishes, and digital images taken at 7.5x using a dissecting microscope. A 1x1-cm grid was then added to the digital CAM images and the number of vessels within each grid counted as a measure of vascularity. In all studies, AGM-1470, a known potent anti-angiogenic agent, was used as a positive control for each experiment at a dose of 10 ng/embryo. Data were then graphed (Figure 1) as a percent of growth factor-induced blood vessel amounts. As can be seen in Figure 1, compounds JY/AG 113-274 and JY/AG 113-283 provided inhibition almost as effective as that of AGM-1470.

### Example 2

#### **Synthesis of the 2,4-Diamino-5(2-alkyl, 2-aryl)vinylfuro[2,3-d] pyrimidines**

To a solution of 2,4-diamino-5-(chloromethyl)furo[2,3-d]pyrimidine, 3, (1.0 g, 5 mmol) in anhydrous DMSO (15 mL) was added tributylphosphine (92%, 1.7g 7.5 mmol), and the resulting mixture was stirred at 60 °C in an oil bath for 3 hrs. under N<sub>2</sub> to form the phosphonium salt. The deep orange solution was then cooled to room temperature. To this solution was added sodium hydride (90% dispersion in mineral oil, 0.2 g, 6 mmol), followed by the desired commercially available aryl alkyl ketone (5.5 mmol). The reaction mixture was stirred at room temperature for 24-32 h. TLC showed the disappearance of the starting 2,4-diamino-5-(chloromethyl)furo[2,3-d]pyrimidine and the formation of two (olefinic) spots. The reaction was quenched with 20 mL methanol, washed with two portions of 50 mL methanol, and the resulting solution was evaporated under reduced pressure to dryness. To the residue was added 6 g of silica gel and CHCl<sub>3</sub> (25 mL) and the slurry was loaded onto 4 x 20 cm dry silica gel column and flash chromatographed initially with CHCl<sub>3</sub> (300 mL), then sequentially with 2% MeOH in CHCl<sub>3</sub> (250 mL); 5 % CH<sub>3</sub>OH in CHCl<sub>3</sub> (300 mL) and 10 % CH<sub>3</sub>OH in CHCl<sub>3</sub> (250 mL). Fractions that showed the desired spot on



TLC were pooled and evaporated to dryness and the residue was recrystallized from ethylacetate to afford the desired olefinic targets.

### Example 3

#### **Synthesis of E/Z-2,4-Diamino-5(2-methyl,2-2'-naphthyl)-vinylfuro[2,3-d]pyrimidine**

Compound 3 (1.0 g, 5 mmol) and 2'-acetonaphthone (940 mg, 5.5 mmol) 28 h afforded 21 (480 mg, 30%) as yellow needles: mp 238.2-247.5 °C;  $R_f$  = 0.55 and 0.52 ( $\text{CH}_3\text{Cl}/\text{CH}_3\text{OH}$  5:1);  $^1\text{H}$  NMR ( $\text{DMSO}-d_6$ ) (E:Z = 2.1) E-isomer  $\delta$  2.34 (s, 3 H, 9- $\text{CH}_3$ ), 6.09 (s, 2 H, 4- $\text{NH}_2$ ), 6.52 (s, 2 H, 2- $\text{NH}_2$ ), 7.05 (s, 1 H, 8-CH), 7.551-7.49 (m, 3 H, 6-CH and  $\text{C}_{10}\text{H}_7$ ), 7.96-7.89 (m, 4 H,  $\text{C}_{10}\text{H}_7$ ), 8.09(s, 1 H,  $\text{C}_{10}\text{H}_7$ ); Z-isomer  $\delta$  2.26 (s, 3 H, 9- $\text{CH}_3$ ), 5.99(s, 2 H, 4- $\text{NH}_2$ ), 6.29 (s, 1 H, 8-CH), 6.54 (s, 2 H, 2- $\text{NH}_2$ ), 6.67 (s, 1 H, 6-CH), 7.13-7.17 (m, 2 H,  $\text{C}_{10}\text{H}_7$ ), 7.70-7.89 (m, 4 H,  $\text{C}_{10}\text{H}_7$ ). Anal. ( $\text{C}_{19}\text{H}_{16}\text{N}_4\text{O}$ ) C, H, N.

### Example 4

#### **Synthesis of (R,S) 2,4-Diamino-5(2-alkyl-2-arylethyl) furo[2,3-d] pyrimidines:**

To a solution of the olefinic intermediate (0.3-0.7 mmol) in a mixture of  $\text{CHCl}_3$  (50 mL) and  $\text{CH}_3\text{OH}$  (15 mL) was added 5% palladium on activated carbon (0.20 g), and the suspension was hydrogenated in a Parr apparatus at room temperature and 40-55 psi for 3-24 h, TLC indicated the disappearance of the starting material and the formation of one major spot. The reaction mixture was filtered through Celite, washed with 30%  $\text{CH}_3\text{OH}$  in  $\text{CHCl}_3$  (3 x 20 mL). After evaporation of the solvent,  $\text{CH}_3\text{OH}$  (50 mL) was added to afford a solution. To this solution was added 5 g silica gel and the mixture was evaporated under reduced pressure to dryness. The silica gel plug was loaded on a dry silica gel column (2 x 16 cm) and flash chromatographed initially with  $\text{CHCl}_3$  (150 mL), then sequentially with 1%  $\text{CH}_3\text{OH}$  in  $\text{CHCl}_3$  (150 mL), 2 %  $\text{CH}_3\text{OH}$  in  $\text{CHCl}_3$  (150 mL), and 5 %  $\text{CH}_3\text{OH}$  in  $\text{CHCl}_3$  (150 mL). Fractions which showed the major spot on TLC were pooled and evaporated to dryness. The residue was recrystallized from  $\text{CH}_3\text{OH}$  or other solvent combinations as indicated to afford the desired target compounds. The yields varied from 50-80%.

### Example 5

#### (R,S) 2,4-Diamino-5(2'-naphthethylpropyl)furo[2,3-d]pyrimidine (37)

(100 mg, 0.3 mmol) 50 psi 5 h afforded 37 (50 mg, 50%) as white crystals: mp 230.2-232 °C;  $R_f$  = 0.57 (EtOH/EtOAc/Hexane 1 :2:1);  $^1\text{H}$  NMR (DMSO- $d_6$ )  $\delta$  1.29-1.31 (d, 3 H, 9-CH<sub>3</sub>), 2.98-3.00 (d, 2 H, 8-CH<sub>2</sub>), 3.09-3.17 (m, 1 H, 9-CH), 3.83 (s, 3 H, OMe), 5.99 (s, 2 H, 4-NH<sub>2</sub>), 6.39 (s, 2 H, 2-NH<sub>2</sub>), 6.88 (s, 1 H, 6-CH), 7.08-7.11 (t, 1 H, C<sub>10</sub>H<sub>7</sub>), 7.24 (d, 1 H, C<sub>10</sub>H<sub>7</sub>), 7.37-7.40 (d, 1 H, C<sub>10</sub>H<sub>7</sub>), 7.61 (s, 1 H, C<sub>10</sub>H<sub>7</sub>), 7.69-7.76 (dd, 2 H, C<sub>10</sub>H<sub>7</sub>). Anal. (C<sub>19</sub>H<sub>18</sub>N<sub>4</sub>O.0.1 H<sub>2</sub>O)C, H, N.

### Example 6

#### 10 *Phospho-EGFR and phospho-Flk1 expression*

A phosphotyrosine ELISA or "cytoblot" on was used on whole cells to determine levels of RTK phosphorylation, as described in Stockwell et al. (Chem Biol 6(2) 71-83 (1999)). A431 human epithelial carcinoma cells (overexpressing EGFR) and U2551 glioblastoma (known to overexpress Flk-1) were seeded at 50 %  
15 confluence into 96-well plates. Cells were allowed to attach and grow overnight in opti-MEM low serum media (Gibco-BRL) to reduce background phosphorylation levels. Cells were then treated with anti-angiogenic compounds for one hour in incomplete medium and then EGF (50 ng/ml) or VEGF (100 ng/ml) was added for 30 minutes. Reactions were stopped by the aspiration of media and the addition of  
20 phosphate buffered saline (PBS) containing 0.05% triton X-100, protease inhibitor cocktail and phosphatase inhibitor cocktail 2 (Sigma Chemical company) for 10 minutes on ice. Cells were then fixed at 60 °C for 30 minutes and then cold methanol added to the cells for five minutes to further permeabilize them for antibody penetration. Cells were blocked for one hour with 1 % bovine serum albumin in PBS,  
25 washed twice in PBS, and then anti-phosphotyrosine-HRP conjugate (Oncogene Research) added at 1:250 dilution overnight. The antibody was then removed, the cells washed three times in PBS with 1% BSA and once with PBS, and luminol-peroxide reagent added (Pierce Biochemical) for 5 minutes. Plates were read for chemilluminescence using a imaging system (ImageStation, Kodak-NEN) for 16x3  
30 seconds and saved as a digitized image. Densitometry of images was then done using NIH Image 1.62 software. Data are graphed as a percentage of growth factor (EGF,

VEGF) treated controls. As can be seen in Figures 4a and 4b, ZY/AG-91 provided excellent inhibition of both EGFR and Flk1 tyrosine kinase activity.

#### Example 7

5 Additional data from the phospho-EGFR and Flk1 assays are presented in Tables 1 (EGFR kinase inhibition), Table 2 (Flk1 kinase inhibition), Table 3 (A431 cytotoxicity) and Table 4 (comparative data showing EGFR, Flk-1, Flt-1 and PDGFR kinase inhibition, A431 cytotoxicity, U251 cytotoxicity inhibition and CAM angiogenesis inhibition. Table 1 identifies the compound, its structure, and the  
10 inhibitory concentration ( $K_{50}$  (mM)) against EGFR kinase. The performance of these compounds was measured against PD153035 and SU5416, both of which are in clinical trials as anti-tumor agents. As can be seen in Table 1, compounds YJ/AG 176 had excellent inhibitory activity, and several other compounds had very good inhibitory activity as well. As can be seen in Tables 1, 2 and 3, many of the  
15 compounds tested had very low  $IC_{50}$  values, comparable to compounds already known to provide significant inhibition of these enzymes such as PD15305 (Traxler, P. *et al.*) and SU5416 (Sun, L. *et al.*). As is understood by one skilled in the art, the lower the  $IC_{50}$  value, the more potent the inhibition of the enzyme.

20 Table 4 provides comparative data indicating that many of the compounds have multiple modes of action.

TABLE 1

## EGFR Kinase Inhibition







| Sample Number | Structure   | IC <sub>50</sub> ( $\mu$ M) |
|---------------|---|-----------------------------|
| YJ/AG 176     |    | 0.2                         |
| YJ/AG 146     |    | 1.2                         |
| YJ/AG 156     |   | 1.7                         |
| YJ/AG 145     |  | 4.3                         |
| YJ/AG 154     |  | 6.2                         |
| YJ/AG 168     |  | 9.2                         |

TABLE 1






|           |   |      |
|-----------|---|------|
| YJ/AG 178 |    | 12.6 |
| YJ/AG 140 |    | 17.4 |
| YJ/AG 148 |    | 19.8 |
| YJ/AG 158 |   | >50  |
| YJ/AG 177 |  | >50  |
| PD153035  |   | 0.2  |
| SU5416    |   | ND   |

TABLE 2

## FK1 Kinase Inhibition








| Sample Number | Structure   | IC <sub>50</sub> ( $\mu$ M) |
|---------------|---|-----------------------------|
| YJ/AG 168     |    | 0.3                         |
| YJ/AG 178     |    | 0.6                         |
| YJ/AG 158     |    | 5.1                         |
| YJ/AG 145     |  | 5.6                         |
| YJ/AG 154     |  | 6                           |
| YJ/AG 177     |  | 9.4                         |
| YJ/AG 176     |  | 28.1                        |

TABLE 2





|           |   |     |
|-----------|---|-----|
| YJ/AG 140 |    | ND  |
| YJ/AG 146 |    | >50 |
| YJ/AG 148 |   | >50 |
| YJ/AG 156 |  | >50 |
| PD153035  |   | ND  |
| SU5416    |   | 2.4 |

TABLE 3

## A4311 Cytotoxicity












| Sample Number | Structure   | IC <sub>50</sub> ( $\mu$ M) |
|---------------|---|-----------------------------|
| YJ/AG 168     |    | 1.2                         |
| YJ/AG 176     |    | 2.8                         |
| YJ/AG 154     |    | 23.5                        |
| YJ/AG 146     |  | 33.2                        |
| YJ/AG 148     |  | 33.5                        |
| YJ/AG 177     |  | 42.1                        |
| YJ/AG 140     |  | ND                          |



TABLE 3

|           |   |      |
|-----------|---|------|
| YJ/AG 145 |    | >50  |
| YJ/AG 158 |    | >50  |
| YJ/AG 178 |   | >50  |
| YJ/AG 156 |  | >50  |
| PD153035  |   | 12.6 |
| SU5416    |   | 19.2 |

**Table 4: Apparent IC<sub>50</sub> (μM) values of AG compounds 9/01**

| COMPOU<br>ND                | EGFR<br>kinase<br>Inhibition | Flk-1<br>kinase<br>Inhibition | Flt-1<br>kinase<br>Inhibition | PDGFR<br>kinase<br>Inhibition | A431cytot<br>oxidity | U251<br>cytotoxicit<br>y Inhibition | CAM<br>angiogenes<br>is<br>Inhibition |
|-----------------------------|------------------------------|-------------------------------|-------------------------------|-------------------------------|----------------------|-------------------------------------|---------------------------------------|
| ✓ YJ/AG 140                 | 17.4                         | ND                            | ND                            | ND                            | ND                   |                                     | ND                                    |
| ✓ YJ/AG 145                 | 4.3                          | 5.6                           | 26.8                          | >50                           | >50                  |                                     | 1.7                                   |
| ✓ YJ/AG 146                 | 1.2                          | >50                           | 15.2                          | >50                           | 33.2                 |                                     | 8.9                                   |
| ✓ YJ/AG 148                 | 19.8                         | >50                           | >50                           | >50                           | 33.5                 |                                     | <0.1<br>(toxic)                       |
| ✓ YJ/AG 154                 | 6.2                          | 6.0                           | ND                            | ND                            | 23.5                 |                                     | <0.1                                  |
| ✓ YJ/AG 156                 | 1.7                          | >50                           | >50                           | >50                           | 31.8                 | 3.4                                 | <0.1                                  |
| ✓ YJ/AG 158                 | >50                          | 5.1                           | 19.2                          | >50                           | >50                  |                                     | <0.1                                  |
| ✓ YJ/AG 168                 | 9.2                          | 0.3                           | >50                           | >50                           | 1.2                  | 5.0                                 | 1.2                                   |
| ✓ YJ/AG 176                 | 0.2                          | 28.1                          | >50                           | 17.0                          | 2.8                  |                                     | 10.8                                  |
| ✓ YJ/AG 177                 | >50                          | 9.4                           | >50                           | 14.7                          | 42.1                 |                                     | 0.4                                   |
| ✓ YJ/AG 178                 | 12.6                         | 0.6                           | 31.1                          | 8.9                           | >50                  |                                     | 1.3                                   |
|                             |                              |                               |                               |                               |                      |                                     |                                       |
| ✗ ZY/AG 70-<br>I            | >50                          | 12.8                          | >50                           | 10.3                          | >50                  |                                     | <0.1                                  |
| ✗ ZY/AG 91                  | >50                          | 2.8                           | >50                           | 8.6                           | >50                  | 1.8                                 | <0.1                                  |
|                             |                              |                               |                               |                               |                      |                                     |                                       |
| ✗ JY/AG 149                 | 2.2                          | 18.4                          |                               |                               | 3.6                  |                                     |                                       |
| ✗ JY/AG 260                 | 0.3                          | >50                           |                               |                               | 28.6                 |                                     |                                       |
| ✗ JY/AG 263                 | 1.6                          | 25.3                          |                               |                               | 38.9                 |                                     |                                       |
| ✗ JY/AG 274                 | 2.2                          | >50                           |                               |                               | >50                  | >50                                 |                                       |
| ✗ JY/AG 275                 | 3.4                          | 42.3                          |                               |                               | 13.2                 |                                     |                                       |
| ✗ JY/AG 276                 | 0.3                          | 49.9                          |                               |                               | 19.6                 |                                     |                                       |
| ✗ JY/AG 282                 | 4.7                          | 16.8                          |                               |                               | >50                  |                                     |                                       |
| ✗ JY/AG 283                 | 4.8                          | ND                            |                               |                               | 8.2                  |                                     |                                       |
| POSITIVE<br>CONTRO<br>LS    |                              |                               |                               |                               |                      |                                     |                                       |
| PD153035                    | 0.2                          |                               |                               |                               | 12.6                 |                                     |                                       |
| SU5416                      |                              | 2.4                           |                               |                               | 19.2                 | 0.2                                 | <0.1                                  |
| cisplatin                   |                              |                               |                               |                               | 8.2                  | 4.2                                 |                                       |
| VEGF<br>kinase<br>Inhibitor |                              |                               | 17.7                          |                               |                      |                                     |                                       |
| AG1295                      |                              |                               |                               | 6.2                           |                      |                                     |                                       |

NOTES:

1. ND = not determined
2. Nomenclature: compound numbers include only the LAST number of sample (E.G., JY/AG 113-282 = JY/AG 282)
- 5 3. A431 cells overexpress the EGFR; U251 cells overexpress Flk1 and PDGFRbeta; HT29 cells do not express EGFR, Flk1, Flt1, or PDGFR at measurable levels

Whereas particular embodiments of this invention have been described above for purposes of illustration, it will be evident to those skilled in the art that

10 numerous variations of the details of the present invention may be made without departing from the invention as defined in the appended claims.

11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
841  
842  
843  
844  
845  
846  
847  
848  
849  
850  
851  
852  
853  
854  
855  
856  
857  
858  
859  
860  
861  
862  
863  
864  
865  
866  
867  
868  
869  
870  
871  
872  
873  
874  
875  
876  
877  
878  
879  
880  
881  
882  
883  
884  
885  
886  
887  
888  
889  
890  
891  
892  
893  
894  
895  
896  
897  
898  
899  
900  
901  
902  
903  
904  
905  
906  
907  
908  
909  
910  
911  
912  
913  
914  
915  
916  
917  
918  
919  
920  
921  
922  
923  
924  
925  
926  
927  
928  
929  
930  
931  
932  
933  
934  
935  
936  
937  
938  
939  
940  
941  
942  
943  
944  
945  
946  
947  
948  
949  
950  
951  
952  
953  
954  
955  
956  
957  
958  
959  
960  
961  
962  
963  
964  
965  
966  
967  
968  
969  
970  
971  
972  
973  
974  
975  
976  
977  
978  
979  
980  
981  
982  
983  
984  
985  
986  
987  
988  
989  
990  
991  
992  
993  
994  
995  
996  
997  
998  
999  
1000  
1001  
1002  
1003  
1004  
1005  
1006  
1007  
1008  
1009  
1010  
1011  
1012  
1013  
1014  
1015  
1016  
1017  
1018  
1019  
1020  
1021  
1022  
1023  
1024  
1025  
1026  
1027  
1028  
1029  
1030  
1031  
1032  
1033  
1034  
1035  
1036  
1037  
1038  
1039  
1040  
1041  
1042  
1043  
1044  
1045  
1046  
1047  
1048  
1049  
1050  
1051  
1052  
1053  
1054  
1055  
1056  
1057  
1058  
1059  
1060  
1061  
1062  
1063  
1064  
1065  
1066  
1067  
1068  
1069  
1070  
1071  
1072  
1073  
1074  
1075  
1076  
1077  
1078  
1079  
1080  
1081  
1082  
1083  
1084  
1085  
1086  
1087  
1088  
1089  
1090  
1091  
1092  
1093  
1094  
1095  
1096  
1097  
1098  
1099  
1100  
1101  
1102  
1103  
1104  
1105  
1106  
1107  
1108  
1109  
1110  
1111  
1112  
1113  
1114  
1115  
1116  
1117  
1118  
1119  
1120  
1121  
1122  
1123  
1124  
1125  
1126  
1127  
1128  
1129  
1130  
1131  
1132  
1133  
1134  
1135  
1136  
1137  
1138  
1139  
1140  
1141  
1142  
1143  
1144  
1145  
1146  
1147  
1148  
1149  
1150  
1151  
1152  
1153  
1154  
1155  
1156  
1157  
1158  
1159  
1160  
1161  
1162  
1163  
1164  
1165  
1166  
1167  
1168  
1169  
1170  
1171  
1172  
1173  
1174  
1175  
1176  
1177  
1178  
1179  
1180  
1181  
1182  
1183  
1184  
1185  
1186  
1187  
1188  
1189  
1190  
1191  
1192  
1193  
1194  
1195  
1196  
1197  
1198  
1199  
1200  
1201  
1202  
1203  
1204  
1205  
1206  
1207  
1208  
1209  
1210  
1211  
1212  
1213  
1214  
1215  
1216  
1217  
1218  
1219  
1220  
1221  
1222  
1223  
1224  
1225  
1226  
1227  
1228  
1229  
1230  
1231  
1232  
1233  
1234  
1235  
1236  
1237  
1238  
1239  
1240  
1241  
1242  
1243  
1244  
1245  
1246  
1247  
1248  
1249  
1250  
1251  
1252  
1253  
1254  
1255  
1256  
1257  
1258  
1259  
1260  
1261  
1262  
1263  
1264  
1265  
1266  
1267  
1268  
1269  
1270  
1271  
1272  
1273  
1274  
1275  
1276  
1277  
1278  
1279  
1280  
1281  
1282  
1283  
1284  
1285  
1286  
1287  
1288  
1289  
1290  
1291  
1292  
1293  
1294  
1295  
1296  
1297  
1298  
1299  
1300  
1301  
1302  
1303  
1304  
1305  
1306  
1307  
1308  
1309  
1310  
1311  
1312  
1313  
1314  
1315  
1316  
1317  
1318  
1319  
1320  
1321  
1322  
1323  
1324  
1325  
1326  
1327  
1328  
1329  
1330  
1331  
1332  
1333  
1334  
1335  
1336  
1337  
1338  
1339  
1340  
1341  
1342  
1343  
1344  
1345  
1346  
1347  
1348  
1349  
1350  
1351  
1352  
1353  
1354  
1355  
1356  
1357  
1358  
1359  
1360  
1361  
1362  
1363  
1364  
1365  
1366  
1367  
1368  
1369  
1370  
1371  
1372  
1373  
1374  
1375  
1376  
1377  
1378  
1379  
1380  
1381  
1382  
1383  
1384  
1385  
1386  
1387  
1388  
1389  
1390  
1391  
1392  
1393  
1394  
1395  
1396  
1397  
1398  
1399  
1400  
1401  
1402  
1403  
1404  
1405  
1406  
1407  
1408  
1409  
1410  
1411  
1412  
1413  
1414  
1415  
1416  
1417  
1418  
1419  
1420  
1421  
1422  
1423  
1424  
1425  
1426  
1427  
1428  
1429  
1430  
1431  
1432  
1433  
1434  
1435  
1436  
1437  
1438  
1439  
1440  
1441  
1442  
1443  
1444  
1445  
1446  
1447  
1448  
1449  
1450  
1451  
1452  
1453  
1454  
1455  
1456  
1457  
1458  
1459  
1460  
1461  
1462  
1463  
1464  
1465  
1466  
1467  
1468  
1469  
1470  
1471  
1472  
1473  
1474  
1475  
1476  
1477  
1478  
1479  
1480  
1481  
1482  
1483  
1484  
1485  
1486  
1487  
1488  
1489  
1490  
1491  
1492  
1493  
1494  
1495  
1496  
1497  
1498  
1499  
1500  
1501  
1502  
1503  
1504  
1505  
1506  
1507  
1508  
1509  
1510  
1511  
1512  
1513  
1514  
1515  
1516  
1517  
1518  
1519  
1520  
1521  
1522  
1523  
1524  
1525  
1526  
1527  
1528  
1529  
1530  
1531  
1532  
1533  
1534  
1535  
1536  
1537  
1538  
1539  
1540  
1541  
1542  
1543  
1544  
1545  
1546  
1547  
1548  
1549  
1550  
1551  
1552  
1553  
1554  
1555  
1556  
1557  
1558  
1559  
1560  
1561  
1562  
1563  
1564  
1565  
1566  
1567  
1568  
1569  
1570  
1571  
1572  
1573  
1574  
1575  
1576  
1577  
1578  
1579  
1580  
1581  
1582  
1583  
1584  
1585  
1586  
1587  
1588  
1589  
1590  
1591  
1592  
1593  
1594  
1595  
1596  
1597  
1598  
1599  
1600  
1601  
1602  
1603  
1604  
1605  
1606  
1607  
1608  
1609  
1610  
1611  
1612  
1613  
1614  
1615  
1616  
1617  
1618  
1619  
1620  
1621  
1622  
1623  
1624  
1625  
1626  
1627  
1628  
1629  
1630  
1631  
1632  
1633  
1634  
1635  
1636  
1637  
1638  
1639  
1640  
1641  
1642  
1643  
1644  
1645  
1646  
1647  
1648  
1649  
1650  
1651  
1652  
1653  
1654  
1655  
1656  
1657  
1658  
1659  
1660  
1661  
1662  
1663  
1664  
1665  
1666  
1667  
1668  
1669  
1670  
1671  
1672  
1673  
1674  
1675  
1676  
1677  
1678  
1679  
1680  
1681  
1682  
1683  
1684  
1685  
1686  
1687  
1688  
1689  
1690  
1691  
1692  
1693  
1694  
1695  
1696  
1697  
1698  
1699  
1700  
1701  
1702  
1703  
1704  
1705  
1706  
1707  
1708  
1709  
1710  
1711  
1712  
1713  
1714  
1715  
1716  
1717  
1718  
1719  
1720  
1721  
1722  
1723  
1724  
1725  
1726  
1727  
1728  
1729  
1730  
1731  
1732  
1733  
1734  
1735  
1736  
1737  
1738  
1739  
1740  
1741  
1742  
1743  
1744  
1745  
1746  
1747  
1748  
1749  
1750  
1751  
1752  
1753  
1754  
1755  
1756  
1757  
1758  
1759  
1760  
1761  
1762  
1763  
1764  
1765  
1766  
1767  
1768  
1769  
1770  
1771  
1772  
1773  
1774  
1775  
1776  
1777  
1778  
1779  
1780  
1781  
1782  
1783  
1784  
1785  
1786  
1787  
1788  
1789  
1790  
1791  
1792  
1793  
1794  
1795  
1796  
1797  
1798  
1799  
1800  
1801  
1802  
1803  
1804  
1805  
1806  
1807  
1808  
1809  
1810  
1811  
1812  
1813  
1814  
1815  
1816  
1817  
1818  
1819  
1820  
1821  
1822  
1823  
1824  
1825  
1826  
1827  
1828  
1829  
1830  
1831  
1832  
1833  
1834  
1835  
1836  
1837  
1838  
1839  
1840  
1841  
1842  
1843  
1844  
1845  
1846  
1847  
1848  
1849  
1850  
1851  
1852  
1853  
1854  
1855  
1856  
1857  
1858  
1859  
1860  
1861  
1862  
1863  
1864  
1865  
1866  
1867  
1868  
1869  
1870  
1871  
1872  
1873  
1874  
1875  
1876  
1877  
1878  
1879  
1880  
1881  
1882  
1883  
1884  
1885  
1886  
1887  
1888  
1889  
1890  
1891  
1892  
1893  
1894  
1895  
1896  
1897  
1898  
1899  
1900  
1901  
1902  
1903  
1904  
1905  
1906  
1907  
1908  
1909  
1910  
1911  
1912  
1913  
1914  
1915  
1916  
1917  
1918  
1919  
1920  
1921  
1922  
1923  
1924  
1925  
1926  
1927  
1928  
1929  
1930  
1931  
1932  
1933  
1934  
1935  
1936  
1937  
1938  
1939  
1940  
1941  
1942  
1943  
1944  
1945  
1946  
1947  
1948  
1949  
1950  
1951  
1952  
1953  
1954  
1955  
1956  
1957  
1958  
1959  
1960  
1961  
1962  
1963  
1964  
1965  
1966  
1967  
1968  
1969  
1970  
1971  
1972  
1973  
1974  
1975  
1976  
1977  
1978  
1979  
1980  
1981  
1982  
1983  
1984  
1985  
1986  
1987  
1988  
1989  
1990  
1991  
1992  
1993  
1994  
1995  
1996  
1997  
1998  
1999  
2000  
2001  
2002  
2003  
2004  
2005  
2006  
2007  
2008  
2009  
2010  
2011  
2012  
2013  
2014  
2015  
2016  
2017  
2018  
2019  
2020  
2021  
2022  
2023  
2024  
2025  
2026  
2027  
2028  
2029  
2030  
2031  
2032  
2033  
2034  
2035  
2036  
2037  
2038  
2039  
2040  
2041  
2042  
2043  
2044  
2045  
2046  
2047  
2048  
2049  
2050  
2051  
2052  
2053  
2054  
2055  
2056  
2057  
2058  
2059  
2060  
2061  
2062  
2063  
2064  
2065  
2066  
2067  
2068  
2069  
2070  
2071  
2072  
2073  
2074  
2075  
2076  
2077  
2078  
2079  
2080  
2081  
2082  
2083  
2084  
2085  
2086  
2087  
2088  
2089  
2090  
2091  
2092  
2093  
2094  
2095  
2096  
2097  
2098  
2099  
2100  
2101  
2102  
2103  
2104  
2105  
2106  
2107  
2108  
2109  
2110  
2111  
2112  
2113  
2114  
2115  
2116  
2117  
2118  
2119  
2120  
2121  
2122  
2123  
2124  
2125  
2126  
2127  
2128  
2129  
2130  
2131  
2132  
2133  
2134  
2135  
2136  
2137  
2138  
2139  
2140  
2141  
2142  
2143  
2144  
2145  
2146  
2147  
2148  
2149  
2150  
2151  
2152  
2153  
2154  
2155  
2156  
2157  
2158  
2159  
2160  
2161  
2162  
2163  
2164  
2165  
2166  
2167  
2168  
2169  
2170  
2171  
2172  
2173  
2174  
2175  
2176  
2177  
2178  
2179  
2180  
2181  
2182  
2183  
2184  
2185  
2186  
2187  
2188  
2189  
2190  
2191  
2192  
2193  
2194  
2195  
2196  
2197  
2198  
2199  
2200  
2201  
2202

## OTHER PUBLICATIONS

- Asano, M., Yukita, A., Matsumoto, T., Kondo, S., and Suzuki, H. (1995). *Cancer Res.* 55, 5296-5301.
- 5 Bikfalvi, A., Javerzat, S., Perollet, C., and Savona, C. (1997). *Bull. Cancer* 84, 885-890.
- Claffey, K.P., Brown, L.F., del Aguila, L.F., Tognazzi, K., Yeo, K., Manseau, E.J., and Dvorak, H.F. (1996). *Cancer Res.* 56, 172-181.
- Cherrington, JM, Strawn, LM, and Shawver, LK (2000). *Adv Cancer Res.* 79, 1-38.
- 10 Folkman, J. (1990). *J. Natl. Cancer Inst.* 82, 4-6.
- Folkman, J. (1995). *Breast Cancer Res. Treat.* 36, 109-118.
- Fontanini, G., Boldrini, L., Chine, S., Pisaturo, F., Calcinai, A., Lucchi, M., Mussi, A., Angeletti, C.A., and Bevilacqua, G. (1999). *Clin. Cancer Res.* 5, 156-161.
- Hanahan, D., and Folkman, J. (1996). *Cell (Cambridge, Mass.)* 86, 353-364
- 15 Hanahan, D., (1997). *Science* 277, 48-50
- Kim, K., Winer, J., Armanini, M., Gillett, N., Phillips, H., and Ferrara, N. (1993). *Nature (London)* 362, 841-844.
- Ohta, Y., Endo, Y., Tanaka, M., Shimizu, J., Oda, M., Hayashi, Y., Watanabe, Y., and Sasaki, T. (1996). *Clin. Cancer Res.* 2, 1411-1416.
- 20 Saleh, M., Stacker, S.A., and Wilks, A.F. (1996). *Cancer Res.* 56, 393-401.
- Shawver, L.K., Lipson, K.E., Fong, T.A.T., McMahon, G., Plowman, G.D. and Strawn, L. (1997). *Drug Discovery* 2, 50-63.
- Takahama, M., Tsutsumi, M., Tsujiuchi, T., Kido, A., Okajima, E., Nezu, K., Tojo, T., Kushibe, K., Kitamura, S., and Konishi, Y. (1998). *Jpn. J. Clin. Oncol.* 28, 176-181
- 25 Takanami, I., Tanaka, F., Hashizume, T., and Kodaira, S. (1997). *Anticancer Res.* 17, 2811-2814